Catalyst Event
Alteogen Inc (196170) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/19/2026, 12:00:00 AM
The second-largest shareholder, holding a 5.05% stake, announced on March 19, 2026, their intention to vote against the re-election of the CFO at the upcoming general meeting, citing a lack of shareholder-friendly policies; a 5-10% price impact is expected.
Korean Translation
지분 5.05%를 보유한 2대 주주가 주주 친화 정책 부족을 이유로 2026년 3월 19일 다가오는 주주총회에서 CFO 재선임에 반대 의사를 표명함; 5-10% 수준의 주가 변동이 예상됨.
Related Recent Events
Daewoong Pharmaceutical Co Ltd (069620) · Other
The Annual General Meeting of Shareholders is scheduled for March 26, 2026, to re-appoint CEO Park Sung-su and add new business purposes; analysts estimate these routine governance matters will result in a 1-5% price impact scheduled.
3/26/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 15th Annual General Meeting of Shareholders including CEO re-appointment on March 26, 2026 scheduled.
3/26/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
A conflict with the Korea Pharmaceutical Distribution Association escalated around March 18, 2026, over a new 'hub wholesaler' policy; analysts estimate the potential boycott and sales disruption will cause a price impact of 5% or more expected.
3/18/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
Partner NovaBridge Biosciences confirmed a potential accelerated approval pathway for gastric cancer treatment Givastomig (ABL111) following a Type B meeting with the U.S. FDA on March 17, 2026. This regulatory milestone for a lead asset is estimated to have a high market impact.
3/17/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
Joint venture Mentis Care to begin joint research with Emory University on March 17, 2026, for AI-based seizure detection expected.
3/17/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a plan for a record-high cash dividend of 2,000 KRW per common share to be approved at the March 31, 2026 AGM; medium importance due to positive impact on shareholder value, scheduled.
3/16/2026, 12:00:00 AM